📣 VC round data is live. Check it out!
- Public Comps
- Cytek Biosciences
Cytek Biosciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Cytek Biosciences and similar public comparables like IBA Group, Sofwave Medical, Beta Bionics, Wellgistics Health and more.
Cytek Biosciences Overview
About Cytek Biosciences
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.
Founded
2014
HQ

Employees
648
Website
Financials (LTM)
EV
$282M
Valuation Multiples
Start free trialCytek Biosciences Financials
Cytek Biosciences reported last 12-month revenue of $204M and negative EBITDA of ($2M).
In the same LTM period, Cytek Biosciences generated $105M in gross profit, ($2M) in EBITDA losses, and had net loss of ($52M).
Revenue (LTM)
Cytek Biosciences P&L
In the most recent fiscal year, Cytek Biosciences reported revenue of $201M and EBITDA of ($663K).
Cytek Biosciences is unprofitable as of last fiscal year, with gross margin of 52%, EBITDA margin of (0%), and net margin of (33%).
Financial data powered by Morningstar, Inc.
Cytek Biosciences Stock Performance
Cytek Biosciences has current market cap of $517M, and enterprise value of $282M.
Market Cap Evolution
Cytek Biosciences' stock price is $4.00.
Cytek Biosciences share price decreased by 12.0% in the last 30 days, and increased by 44.6% in the last year.
Cytek Biosciences has an EPS (earnings per share) of $-0.52.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $282M | $517M | 0.0% | -12.0% | -10.6% | 44.6% | $-0.52 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCytek Biosciences Valuation Multiples
Cytek Biosciences trades at 1.4x EV/Revenue multiple, and (176.7x) EV/EBITDA.
EV / Revenue (LTM)
Cytek Biosciences Financial Valuation Multiples
As of May 26, 2026, Cytek Biosciences has market cap of $517M and EV of $282M.
Cytek Biosciences has a P/E ratio of (10.0x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Cytek Biosciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Cytek Biosciences Margins & Growth Rates
Cytek Biosciences grew revenue by 4% and EBITDA by 353% in the last fiscal year.
In the most recent fiscal year, Cytek Biosciences reported gross margin of 52%, EBITDA margin of (0%), and net margin of (33%).
Cytek Biosciences Margins
Cytek Biosciences Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Cytek Biosciences Operational KPIs
Cytek Biosciences' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Cytek Biosciences' Rule of 40 is 2% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cytek Biosciences' Rule of X is 8% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Cytek Biosciences Competitors
Cytek Biosciences competitors include IBA Group, Sofwave Medical, Beta Bionics, Wellgistics Health, 2seventy bio, MiMedx Group, Cerus, AngioDynamics, The Beauty Tech Group and Tactile Medical.
Most Cytek Biosciences public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 0.8x | 0.8x | 11.2x | 10.6x | |||
| 5.6x | — | 64.6x | — | |||
| 3.3x | 2.9x | (6.3x) | (5.2x) | |||
| 24.0x | — | (6.0x) | — | |||
| 11.2x | — | (4.3x) | — | |||
| 1.0x | 1.1x | 3.8x | 5.9x | |||
| 2.4x | 2.3x | 58.8x | 41.3x | |||
| 1.5x | 1.4x | 59.6x | 36.6x | |||
This data is available for Pro users. Sign up to see all Cytek Biosciences competitors and their valuation data. Start Free Trial | ||||||
Cytek Biosciences Funding History
Before going public, Cytek Biosciences raised $144M in total equity funding, across 3 rounds.
Last private valuation of Cytek Biosciences was $43M, after raising $12M in January 2017 from Easy Prosperity, Eight Roads Ventures, and F-Prime.
Cytek Biosciences Funding Rounds
Cytek Biosciences M&A Activity
Cytek Biosciences has acquired 2 companies to date.
Last acquisition by Cytek Biosciences was on February 13th 2023. Cytek Biosciences acquired Flow Cytometry & Imaging for $45M (EV/Revenue multiple of ).
Latest Acquisitions by Cytek Biosciences
| Description | Flow Cytometry & Imaging is a division under DiaSorin managing Luminex technologies for flow cytometry and imaging assays. It encompasses commercial operations, R&D, and support for multiplexed analysis systems used in clinical diagnostics and research laboratories worldwide. | Tonbo Biosciences is a San Diego-based supplier of reagents for cell analysis in life sciences research. Its portfolio covers flow cytometry antibodies, cell isolation kits, PCR assays, and cell culture media targeting immunology, apoptosis, and immune profiling applications. The company distributes fluorescent dyes and viability stains compatible with major cytometers like BD FACSCalibur and Beckman Coulter models. Tonbo supports academic labs and biotech firms with bulk reagents and custom conjugations. |
| HQ Country | ||
| HQ City | Austin, TX | San Diego, CA |
| Deal Date | 13 Feb 2023 | 3 Nov 2021 |
| Valuation | $45M | $17M |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all Cytek Biosciences acquisitions and their M&A valuation multiples. Start Free Trial | ||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Cytek Biosciences
| When was Cytek Biosciences founded? | Cytek Biosciences was founded in 2014. |
| Where is Cytek Biosciences headquartered? | Cytek Biosciences is headquartered in United States. |
| How many employees does Cytek Biosciences have? | As of today, Cytek Biosciences has over 648 employees. |
| Who is the CEO of Cytek Biosciences? | Cytek Biosciences' CEO is Wenbin Jiang. |
| Is Cytek Biosciences publicly listed? | Yes, Cytek Biosciences is a public company listed on Nasdaq. |
| What is the stock symbol of Cytek Biosciences? | Cytek Biosciences trades under CTKB ticker. |
| When did Cytek Biosciences go public? | Cytek Biosciences went public in 2021. |
| Who are competitors of Cytek Biosciences? | Cytek Biosciences main competitors include IBA Group, Sofwave Medical, Beta Bionics, Wellgistics Health, 2seventy bio, MiMedx Group, Cerus, AngioDynamics, The Beauty Tech Group, Tactile Medical. |
| What is the current market cap of Cytek Biosciences? | Cytek Biosciences' current market cap is $517M. |
| What is the current revenue of Cytek Biosciences? | Cytek Biosciences' last 12 months revenue is $204M. |
| What is the current revenue growth of Cytek Biosciences? | Cytek Biosciences revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Cytek Biosciences? | Current revenue multiple of Cytek Biosciences is 1.4x. |
| Is Cytek Biosciences profitable? | No, Cytek Biosciences is not profitable. |
| What is the current EBITDA of Cytek Biosciences? | Cytek Biosciences has negative EBITDA and is not profitable. |
| What is Cytek Biosciences' EBITDA margin? | Cytek Biosciences' last 12 months EBITDA margin is (1%). |
| What is the current EV/EBITDA multiple of Cytek Biosciences? | Current EBITDA multiple of Cytek Biosciences is (176.7x). |
| How many companies Cytek Biosciences has acquired to date? | As of May 2026, Cytek Biosciences has acquired 2 companies. |
| What was the largest acquisition by Cytek Biosciences? | $45M acquisition of Flow Cytometry & Imaging on 13th February 2023 was the largest M&A Cytek Biosciences has done to date. |
| What companies Cytek Biosciences acquired? | Cytek Biosciences acquired Flow Cytometry & Imaging and Tonbo Biosciences. |
| In how many companies Cytek Biosciences has invested to date? | Cytek Biosciences hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Cytek Biosciences
Lists including Cytek Biosciences
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
